Interventional Cardiology Devices Market Analysis and Forecast to 2031: By Type (Angioplasty Balloons, Angioplasty Stents, Structural Heart Devices, Catheters, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, Other Devices), End User (Hos

Interventional Cardiology Devices Market Analysis and Forecast to 2031: By Type (Angioplasty Balloons, Angioplasty Stents, Structural Heart Devices, Catheters, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, Other Devices), End User (Hospitals, Ambulatory Surgical Centers, Others), and Region

The global interventional cardiology devices market was valued at USD 13.8 billion in 2021 and it is anticipated to grow further to USD 40.4 billion by 2031, at a CAGR of 11.3% during the forecast period.


Catheters are used in interventional cardiology to treat heart conditions. The procedure involves introducing a device, such as a balloon, stent, catheter, or another device, into the femoral artery or any other significant peripheral artery or vein, followed by the cannulation of the heart with the use of an X-ray. Additionally, a range of interventional cardiology tools is used to treat peripheral vascular issues that have an impact on the circulatory system and can result in the buildup of plaque in the arteries of the limbs. Some of the commercially available interventional cardiology devices include catheters, balloons, stents, and filters.

Market Trends and Drivers

The most prevalent form of heart disease in the US, coronary artery disease (CAD), claimed 365,914 lives in 2017, according to the Centers for Disease Control and Prevention (CDC). Additionally, according to the CDC's estimations, 18.2 million Americans over the age of 20 currently have CAD. The British Heart Foundation estimates that 2.3 million persons in the UK had CAD as of June 2020. In the UK, heart and circulatory illnesses cause 170,000 deaths annually. The need for interventional cardiology devices is anticipated to rise in the upcoming years due to the enormous patient population and the high mortality rate.


The need for interventional cardiology equipment is also fueled by risk factors including diabetes and hypertension. Diabetes increases the likelihood of developing additional disorders that increase the risk of coronary heart disease. High blood sugar levels over time might harm the heart's blood vessels. The International Diabetes Federation (IDF) projects that there will be 700 million individuals with diabetes worldwide by 2045, up from 463 million in 2019. Every year, 1.5 million people in the US alone are given a diabetes diagnosis [Source: American Diabetes Association (ADA)]. The rise in the number of elderly people can be partly blamed for the rise in diabetes prevalence.

Market Restraints and Challenges

The availability of efficient first-line treatments and the strict regulatory environment for the manufacture of interventional cardiology devices are anticipated to limit the market growth.

Global Interventional Cardiology Devices Market Segmental Overview

The report analyses the global interventional cardiology devices market based on the type, end user, and region.

Global Interventional Cardiology Devices Market by Type

Based on the type, it is segmented into Inferior Angioplasty Balloons, Angioplasty Stents, Structural Heart Devices, Catheters, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, Other Devices. The angioplasty balloons segment is anticipated to dominate the market during the forecast period. The key factors such as increasing demand for minimally invasive procedures coupled with the high prevalence of cardiovascular diseases are propelling the growth of the market.

Global Interventional Cardiology Devices Market by End User

Based on the end user, it is segmented into hospitals, ambulatory surgical centers, and others. The hospital segment is likely to dominate the market during the forecast period. Positive market effects result from rising public awareness of various medical therapies. Additionally, one of the main market possibilities for interventional cardiology equipment is the development of healthcare infrastructure in developing nations.

Geographical Analysis of the Global Interventional Cardiology Devices Market

Region-wise it is studied across North America, Europe, Asia Pacific, and the Rest of the World. The North America accounted for the largest share of the interventional cardiology devices market. The large share of the market is primarily attributed to factors such as the increasing prevalence of diabetes coupled with rising aging population, availability of reimbursement, and the presence of all key players.

Major Players in the Global Interventional Cardiology Devices Market COVID-19 Impact

The COVID-19 outbreak has had an effect on the market for interventional cardiology equipment as well as other areas of the medical device business globally. Despite the availability of emergency and outpatient department (OPD) services in cardiology departments, the number of patient visits to hospitals has decreased dramatically over the last six months. Patient visits have dramatically decreased as a result of widespread lockdowns and social isolation policies. The sales of interventional cardiology goods have been further decreased as a result. Many of the industry's top companies, including Boston Scientific, Medtronic, and Abbott, have reported declining revenues for the second and third quarters of 2020.

Recent Developments

• July 2021, Abbott launched its XIENCE family of stents, which received the US Food and Drug Administration’s approval for one-month DAPT labelling for high bleeding risk patients in the United States. In addition, XIENCE stents recently received the CE Mark approval for DAPT in 28 days, thus, ensuring XIENCE stents the shortest DAPT indication in the world.
• May 2021, NiTiDES, a novel polymer-free self-expanding Amphilimus eluting stent from Alvimedia for superficial femoral artery (SFA) lesions, received the CE mark.
• June 2020, Edward LifeSciences Corporation has received Chinese regulatory approval for the SAPIEN 3 Transcatheter Heart Valve for the treatment patients suffering from severe, symptomatic aortic stenosis who are unable to undergo open-heart surgery.
• September 2019, Medtronic has received US FDA approval for its Next-Generation Evolut PRO+ TAVR System for the treatment of symptomatic severe aortic stenosis in patients.
• March 2019, Abbott has received US FDA approval for its Mitra Clip Heart Valve Repair Device to treat mitral regulation.

Frequently Asked Questions

Q1. How big is the Interventional Cardiology Devices market?Ans. The global Interventional Cardiology Devices market size was USD 13.8 Billion in 2021 and is anticipated to reach USD 40.4 Billion in 2031, growing at a rate of 11.3% from 2022 to 2031.
Q2. What is the Interventional Cardiology Devices market growth rate?Ans. The growth rate of the Interventional Cardiology Devices market is 11.3%.
Q3. Which region holds a major market share for the Interventional Cardiology Devices market?Ans. North America holds a major market share of the Interventional Cardiology Devices market in 2021.
Q4. Which segment accounted for the largest Interventional Cardiology Devices market share?Ans. By end user, hospitals segment accounted for the largest Interventional Cardiology Devices market share.
Q5. Who are the key players in the Interventional Cardiology Devices market?
Q6. What are the factors driving the Interventional Cardiology Devices market growth?Ans. The major factors driving the growth of the market are the growing healthcare market in emerging countries.
Q7. What are the key growth strategies of Interventional Cardiology Devices market players?Ans. The key growth strategies of Interventional Cardiology Devices market players are product launch and product approval.
Q8. Which region will provide more business opportunities for the Interventional Cardiology Devices market during the forecast period?Ans. The Asia-Pacific region will provide more business opportunities for the Interventional Cardiology Devices market during the forecast period.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.